Organometallics
Article
time. After the 48 h, the reaction mixture was cooled to −10 °C, and
the precipitate was filtered off. The residue was washed with cold abs.
ethanol (6 mL) and n-pentane (6 mL). Compound 3 is an orange
solid (1.35 g, 1.56 mmol, 67%).
126.66, 83.22, 64.92, 32.65, 29.50, 18.50, 18.30, 17.28, 17.22, 14.79,
14.62, 13.06, 12.73, 12.06. 19F NMR (CDCl3, 471 MHz): δ −81.21
(s, 3F, CF3), −148.84 (m, 4F, BF2). ESI HR-MS m/z: calcd for
C61H74IrB2F4N6 [M − H]+, 1410.57415; found, 1410.57436.
Synthesis of [IrCl(CO)2(4)]. To a Schlenk flask (10 mL) equipped
with stirring bar and septum were added [IrCl(cod)(4)] (40 mg,
0.0329 mmol) and dry CH2Cl2 (5 mL). A balloon with carbon
monoxide was connected through a cannula, and CO was bubbled
through the stirred solution during 30 min. The reaction mixture was
concentrated under reduced pressure, then pentane was added, and
the resulting precipitate was filtered off and washed with pentane. The
resulting product is an orange solid (30 mg, 0.0258 mmol, yield 78%).
1H NMR (300 MHz, CDCl3): δ 7.35 (s, 2H, N−CH−CH−N),
7.19 (s, 4H, 4H m-Ar), 2.55 (s, 12H), 2.33−2.30 (m, 20H, 4× CH3,
4× CH2 Bodipy), 1.49 (s, 12H), 1.05−0.98 (m, 12H, 4× CH3
Bodipy). 13C NMR (126 MHz, CDCl3): δ 179.75, 176.87, 168.48,
155.07, 153.34, 139.54, 138.81, 137.67, 137.32, 136.88, 133.53,
132.70, 131.11, 128.71, 123.82, 18.82, 17.24, 14.83, 14.70, 12.95,
12.78, 12.64, 12.36. 19F NMR (471 MHz, CDCl3): δ −148.77,
−148.98 (m, 4F, BF2). ESI HR-MS m/z: calcd for
C55H63IrB2ClF4N6O2 [M − H]+, 1165.44470; found, 1165.44588.
Synthesis of [PdCl(allyl)(4)]. 4·HCl (50 mg, 0.0545 mmol, 1
equiv), [PdCl(allyl)]2 (10.0 mg, 0.0273 mol, 0.5 equiv), and K2CO3
(22.6 mg, 0.164 mmol, 3 equiv) were suspended in acetone (3 mL).
Next, the mixture was stirred at 60 °C for 4 h. The volatiles were
removed in vacuo, and CH2Cl2 (3 mL) was added to the residue. The
mixture was filtered through a silica plug and the filtrate dried in
vacuo. The solution was evaporated and purified by column
chromatography (Cy/EA 1:1). An orange solid was obtained (40
mg, 0.0376 mmol, 69%).
1H NMR (CDCl3, 500 MHz): δ 8.22 (s, 2H, CH), 7.04 (s, 4H,
CH), 2.54 (s, 12H, CH3), 2.33 (q, 8H, CH2), 2.26 (s, 12H, CH3),
1.42 (s, 12H, CH3), 1.01 (t, 12H, CH3). 13C NMR (CDCl3, 126
MHz): δ 163.84, 153.33, 150.33, 140.18, 138.40, 132.55, 131.05,
128.30, 127.59, 18.38, 17.24, 14.76, 12.64, 12.10. 19F NMR (CDCl3,
471 MHz): δ −148.84 (m, 4F, BF2). ESI HR-MS m/z: calcd for
C52H63B2F4N6 [M]+, 869.52310; found, 869.52447.
Synthesis of Imidazolium Salt 4·HCl. A 25 mL Schlenk flask
was charged with diimine 3 (300 mg, 0.345 mmol, 1 equiv),
paraformaldehyde (10.5 mg, 0.349 mmol, 1.01 equiv), Me3SiCl (37.6
mg, 44 μL, 0.347 mmol, 1 equiv), and abs. EtOAc (12 mL). The
reaction mixture was heated to 70 °C for 48 h. The suspension was
cooled to room temperature, and the solvent was removed under
reduced pressure. The residue was purified by column chromatog-
raphy (CHCl3/MeOH 10:1). The desired product is an orange solid
(163 mg, 0.178 mmol, 51%).
1H NMR (300 MHz, CDCl3): δ 11.97 (s, 1H, CH), 7.64 (s, 2H,
CH), 7.28 (s, 4H, CH), 2.53 (s, 12H, CH3), 2.37 (s, 12H, CH3), 2.31
(t, 8H, CH2), 1.47 (s, 6H, CH3), 1.41 (s, 6H, CH3), 1.01 (t, 6H,
CH3), 0.97 (t, 6H, CH3). 13C NMR (126 MHz, CDCl3): δ 155.66,
153.54, 141.66, 139.79, 139.48, 137.49, 136.88, 135.85, 133.89,
133.46, 132.85, 130.83, 129.96, 129.65, 124.13, 77.16, 18.08, 17.20,
17.13, 14.75, 14.60, 13.06, 12.73, 12.58, 12.28. 19F NMR (471 MHz,
CDCl3): δ −148.69, −148.89 (m, 4F, BF2). ESI HR-MS m/z: calcd
for C53H63B2F4N6 [M]+, 881.52310; found, 881.52488.
Synthesis of [IrCl(cod)(4)]. To a Schlenk tube (10 mL) equipped
with a stirring bar and 4·HCl (50 mg, 0.0545 mmol, 1 equiv) were
added Ag2O (6.3 mg, 0.0273 mmol, 0.5 equiv) and CH2Cl2 (5 mL).
The reaction mixture was heated to 40 °C for 3 h, and the solvent was
removed under reduced pressure. The remaining residue was
suspended in toluene. Next, [IrCl(cod)]2 (17.3 mg, 0.0273 mmol,
0.5 equiv) was added to the suspension and allowed to react for 4 h at
100 °C. The solution was filtered through Celite, evaporated, and
purified by chromatography (EA). The volatiles were removed to give
product [IrCl(cod)(4)] as an orange solid (60 mg, 0.0593 mmol,
90%).
1H NMR (500 MHz, CDCl3): δ 7.28 (s, 2H, N−CH−CH−N),
7.19−7.09 (m, 4H, 4H m-Ar), 4.85 (m, 1H, allyl), 3.94−3.87 (m, 1H,
allyl), 3.32 (d, J = 6.5 Hz, 1H, allyl), 2.79 (d, J = 13.5 Hz, 1H, allyl),
2.53 (m, 12H, 4× CH3), 2.34−2.27 (m, 20H, 4× CH3, 4× CH2
Bodipy), 1.97 (d, J = 12.0 Hz, 1H, allyl), 1.45 (s, 6H, 2× CH3), 1.37
(s, 6H, 2× CH3), 1.08−0.92 (m, 12H, 4× CH3 Bodipy). 13C NMR
(126 MHz, CDCl3): δ 184.82, 154.69, 153.60, 139.04, 138.73, 138.66,
137.60, 137.25, 137.08, 133.32, 132.80, 130.87, 130.37, 128.47,
123.38, 114.19, 72.85, 49.30, 29.81, 18.52, 18.49, 17.24, 17.16, 14.77,
14.71, 12.70, 12.61, 12.56, 12.18, 1.13. 19F NMR (282 MHz, CDCl3):
δ −148.79, −149.13 (m, 4F, BF2). ESI HR-MS m/z: calcd for
C56H67B2F4N6Pd [M]+, 1027.457882; found, 1027.460295.
Synthesis of [PdCl2(Clpy)(4)]. A Schlenk flask equipped with a
stirring bar was loaded with imidazolium salt 4·HCl (50 mg, 0.0545
mmol, 1 equiv), PdCl2 (9.67 mg, 0.0545 mmol, 1 equiv), and K2CO3
(37.7 mg, 0.273 mmol, 5 equiv). 3-Chloropyridine (1.0 mL) was
added, and the mixture was stirred at 80 °C in a sealed flask overnight.
The reaction mixture was filtered through Celite, and the filtrate was
evaporated under reduced pressure. The orange residue was dissolved
in a minimum amount of CH2Cl2, filtered, and precipitated with n-
pentane. The product was obtained as an orange solid (54 mg, 0.0461
mmol, 85%).
1H NMR (CDCl3, 500 MHz): δ 7.19 (s, 4H, CH), 6.98 (s, 2H,
CH), 4.29 (s, 2H, CH), 3.13 (s, 2H, CH), 2.56 (s, 6H, CH3), 2.55 (s,
6H, CH3), 2.46 (s, 6H, CH3), 2.34 (m, 14H, CH3/CH2), 1.90−1.80
(m, 4H, CH2), 1.67 (s, 6H, CH3), 1.61−1.46 (m, 4H, CH2), 1.36 (s,
6H, CH3), 1.025 (t, 6H, CH3), 1.015 (t, 6H, CH3). 13C NMR
(CDCl3, 126 MHz): δ 180.51, 154.82, 153.48, 139.32, 139.11, 137.50,
136.83, 133.28, 132.83, 130.76, 130.63, 129.12, 127.94, 124.10, 84.44,
77.42, 77.16, 76.91, 51.74, 33.74, 29.19, 19.99, 18.47, 17.28, 17.24,
14.78, 13.27, 12.75, 12.63, 11.85. 19F NMR (CDCl3, 471 MHz): δ
−148.90 (m, 4F, BF2). ESI HR-MS m/z: calcd for C61H74IrB2F4N6
[M]+, 1181.57210; found, 1181.57433.
Synthesis of [Ir(cod)(4)(py)]OTf. To a flame-dried Schlenk flask
containing [IrCl(cod)(4)] (41.2 mg, 33.9 mmol, 1 equiv) was added
CH2Cl2 (5 mL), followed by pyridine (4.1 μL, 4.0 mg, 50.8 μmol, 1.5
equiv) and [Ag(CF3SO3)] (8.7 mg, 33.9 μmol, 1 equiv). The reaction
mixture was stirred for 1 h and then filtered through a Celite plug.
The filtrate was evaporated under reduced pressure. The solid residue
was dissolved in a minimum amount of CH2Cl2 and precipitated from
diethyl ether. The precipitate was collected by filtration and dried
under vacuum. The product was obtained as an orange microcrystal-
line solid (46.8 mg, 33 μmol, yield 98%).
1H NMR (500 MHz, CD2Cl2): δ 8.62 (d, J = 2.4 Hz, 1H), 8.52
(dd, J = 5.6, 1.4 Hz, 1H), 7.75 (dt, J = 8.4, 1.7 Hz, 1H), 7.32 (s, 2H),
7.26 (s, 5H), 7.24−7.18 (m, 1H), 2.59−2.50 (m, 16H), 2.47 (s, 14H),
2.39 (q, J = 7.6 Hz, 4H), 2.31 (q, J = 7.6 Hz, 4H), 1.62 (s, 7H), 1.56
(s, 7H), 1.05 (t, J = 7.5 Hz, 6H), 0.99 (t, J = 7.5 Hz, 7H). 13C NMR
(126 MHz, CD2Cl2): δ 154.68, 154.11, 153.35, 150.69, 149.79,
140.16, 139.64, 138.73, 138.61, 138.56, 137.48, 133.74, 133.50,
132.56, 131.37, 130.86, 128.98, 125.14, 124.98, 30.29, 19.67, 17.64,
17.61, 15.05, 15.00, 13.29, 12.89, 12.62. 19F NMR (471 MHz,
CD2Cl2): δ −147.78, −147.99 (m, 4F, BF2). ESI HR-MS m/z: calcd
for C58H67B2Cl3F4N7Pd [M]+, 1170.36751; found, 1170.37199.
Synthesis of [AuCl(4)]. To a round-bottom flask (5 mL)
equipped with a stirring bar were added imidazolium salt 4·HCl
(50 mg, 0.0545 mmol, 1 equiv), [AuCl(Me2S)] (16.1 mg, 0.0545
mmol, 1 equiv), K2CO3 (7.5 mg, 0.0545 mmol, 1 equiv), and acetone
(3 mL). The flask was sealed, and the reaction mixture was stirred at
60 °C for 12 h. The solution was filtered, evaporated, and purified by
column chromatography (Cy/EA). The volatiles were removed to
1H NMR (500 MHz, CDCl3): δ 8.23 (d, 2H, CH), 7.85 (t, 1H,
CH), 7.47 (t, 2H, CH), 7.35 (s, 2H, CH), 7.27 (s, 2H, CH), 7.25 (s,
2H, CH), 4.01 (m, 2H, CH2), 3.28 (m, 2H, CH2), 2.57 (s, 6H, CH3),
2.55 (s, 6H, CH3), 2.38 (s, 6H, CH3), 2.32 (t, 4H, CH2), 2.31 (t, 4H,
CH2), 2.00 (m, 4H, CH2), 1.81 (s, 6H, CH3), 1.77 (s, 6H, CH3), 1.70
(m, 4H, CH2), 1.30 (s, 6H, CH3), 1.05 (t, 6H, CH3), 1.00 (t, 6H,
CH3). 13C NMR (126 MHz, CDCl3): δ 174.55, 155.40, 154.20,
150.74, 139.14, 138.61, 138.55, 138.27, 138.00, 137.59, 137.21,
136.40, 133.93, 133.13, 131.08, 130.05, 129.68, 129.39, 126.71,
H
Organometallics XXXX, XXX, XXX−XXX